生产企业：Armata Pharmaceuticals, Inc.
AP-PA02 is an inhaled bacteriophage product candidate developed by Armata Pharmaceuticals, Inc. that has completed Phase 2 clinical studies in cystic fibrosis (CF) and non-CF bronchiectasis (NCFB) patients with chronic pulmonary Pseudomonas aeruginosa infection.
AP-PA02 is an inhaled bacteriophage product candidate developed by Armata Pharmaceuticals, Inc. that has completed Phase 2 clinical studies in cystic fibrosis (CF) and non-CF bronchiectasis (NCFB) patients with chronic pulmonary Pseudomonas aeruginosa infection.
